Kymera Therapeutics, Inc. (KYMR)
121.05
+1.25
(+1.04%)
USD |
NASDAQ |
Aug 24, 16:00
121.01
-0.04
(-0.03%)
After-Hours: 20:00
Kymera Therapeutics Enterprise Value : 9.409B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 9.409B |
| August 21, 2026 | 9.306B |
| August 20, 2026 | 9.446B |
| August 19, 2026 | 9.927B |
| August 18, 2026 | 9.436B |
| August 17, 2026 | 9.439B |
| August 14, 2026 | 9.106B |
| August 13, 2026 | 8.860B |
| August 12, 2026 | 8.828B |
| August 11, 2026 | 8.463B |
| August 10, 2026 | 8.377B |
| August 07, 2026 | 8.289B |
| August 06, 2026 | 8.197B |
| August 05, 2026 | 8.120B |
| August 04, 2026 | 8.030B |
| August 03, 2026 | 7.692B |
| July 31, 2026 | 7.948B |
| July 30, 2026 | 8.247B |
| July 29, 2026 | 8.101B |
| July 28, 2026 | 8.176B |
| July 27, 2026 | 8.498B |
| July 24, 2026 | 8.541B |
| July 23, 2026 | 8.526B |
| July 22, 2026 | 8.522B |
| July 21, 2026 | 8.773B |
| Date | Value |
|---|---|
| July 20, 2026 | 8.582B |
| July 17, 2026 | 8.972B |
| July 16, 2026 | 8.825B |
| July 15, 2026 | 8.835B |
| July 14, 2026 | 8.666B |
| July 13, 2026 | 8.527B |
| July 10, 2026 | 9.268B |
| July 09, 2026 | 9.239B |
| July 08, 2026 | 8.839B |
| July 07, 2026 | 9.259B |
| July 06, 2026 | 8.888B |
| July 02, 2026 | 8.785B |
| July 01, 2026 | 8.842B |
| June 30, 2026 | 8.881B |
| June 29, 2026 | 8.414B |
| June 26, 2026 | 8.315B |
| June 25, 2026 | 9.000B |
| June 24, 2026 | 7.637B |
| June 23, 2026 | 7.504B |
| June 22, 2026 | 7.603B |
| June 18, 2026 | 6.861B |
| June 17, 2026 | 6.818B |
| June 16, 2026 | 6.616B |
| June 15, 2026 | 6.464B |
| June 12, 2026 | 6.514B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.02B |
| Oncolytics Biotech, Inc. | 101.54M |
| Sangamo Therapeutics, Inc. | 58.03M |
| Sarepta Therapeutics, Inc. | 2.172B |
| Anixa Biosciences, Inc. | 108.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.21M |
| Revenue (Quarterly) | 65.00M |
| Total Expenses (Quarterly) | 126.21M |
| EPS Diluted (Quarterly) | -0.6235 |
| Gross Profit Margin (Quarterly) | 96.88% |
| Profit Margin (Quarterly) | -94.17% |
| Earnings Yield | -2.68% |
| Normalized Earnings Yield | -2.653 |